Pharmaceutical

Arbutus Biopharma Corporation (NASDAQ:ABUS) has announced its third quarter financial results for 2015.

Arbutus Biopharma Corporation (NASDAQ:ABUS) has announced its third quarter financial results for 2015.
According to the press release:

“We are excited to advance the development of our lead HBV candidate, TKM-HBV, to a Phase II, multi-dosing, clinical trial that will measure hepatitis B surface antigen (HBsAg) reduction in HBV infected patients,” said Dr. Mark J. Murray, Arbutus’ President and CEO. “We are also accelerating the development of our other promising HBV candidates, in particular, those that target cccDNA formation and core protein/capsid assembly.”

Some company highlights include:

    • Arbutus announced progression of TKM-HBV to Phase II studies in HBV infected patients based on results from a Phase I single ascending dose study. The TKM-HBV product candidate that will be studied in Phase II will be referred to as ARB-1467.
    • Arbutus presented preclinical HBV data at the 2015 International Meeting on Molecular Biology of Hepatitis B Viruses, held on October 4-8, 2015. The presentations were titled: 1) “Profiling the Effects of TKM-HBV on cccDNA in Humanized Chimeric Mouse Model of HBV”; 2) “TKM-HBV, a Novel RNA Interference Treatment for Chronic Hepatitis B, Mediates Global Viral Antigen Reductions through a Well-Defined Mechanism of Action”; and 3) “Novel Inhibitors of HBV cccDNA Formation Exhibit Synergistic Effects with Nucleoside and Nucleotide Analog.”

Click here to read the full press release.

 
 

MARKETS

Markets
TSX19692.92+236.21
TSXV646.04+10.63
DOW32823.77-21.36
S&P 5004118.09-12.20
NASD12359.15-31.54
ASX6945.20+55.50

COMMODITIES

Commodities
Gold1767.79+5.92
Silver20.27+0.07
Copper3.52-0.05
Palladium2191.00+89.00
Platinum908.00+11.00
Oil93.83-4.79
Heating Oil3.43-0.12
Natural Gas8.27+0.04

DOWNLOAD FREE REPORTS

×